Mercados españoles cerrados

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
68,08-2,08 (-2,96%)
A partir del 01:57PM EDT. Mercado abierto.

CRISPR Therapeutics AG

Baarerstrasse 14
Zug 6300
Switzerland
41 41 561 32 77
https://www.crisprtx.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo407

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Samarth Kulkarni Ph.D.CEO & Chairman1,31M10,55M1978
Mr. James R. KasingerGeneral Counsel & Secretary709,25kN/A1972
Mr. Shaun FoyFounderN/AN/AN/A
Dr. Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board MemberN/AN/AN/A
Dr. Chad A. Cowan Ph.D.Scientific FounderN/AN/AN/A
Dr. Matthew Porteus M.D., Ph.D.Scientific Founder & Advisory Board MemberN/AN/A1966
Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board MemberN/AN/AN/A
Dr. Raju Yashaswi Prasad Ph.D.Chief Financial OfficerN/AN/A1984
Mr. Stephen KennedyHead of Technical OperationsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Gobierno corporativo

El ISS Governance QualityScore de CRISPR Therapeutics AG, a día 1 de marzo de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 9; Derechos de los accionistas: 2; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.